# Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

> **NCT03117855** · PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Bile Duct Adenocarcinoma
- Stage III Intrahepatic Cholangiocarcinoma
- Stage IVA Intrahepatic Cholangiocarcinoma
- Stage IVB Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Radioembolization

## Key facts

- **NCT ID:** NCT03117855
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2019-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company no longer interested in supporting this trial
- **Last updated:** 2017-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117855, "Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03117855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*